Warnex Inc.

Warnex Inc.

October 05, 2005 07:01 ET

Warnex technology adopted by Gelda Scientific

LAVAL, QC, Oct. 5 - Warnex Inc. (TSX:WNX) today announced that
Gelda Scientific, a leading commercial laboratory based in Mississauga,
Ontario, will offer pathogen testing services using the Warnex™ Rapid
Pathogen Detection System. Gelda Scientific will use the Warnex food safety
technology to test for strains of E. coli O157, Listeria and Salmonella.

Established in 1978, Gelda Scientific (www.gelda.com) provides laboratory
testing services to the food and beverage, cosmetic, water and pharmaceutical
sectors. Gelda labs are accredited by ISO, CAEAL, MOE, CFIA and Health Canada.
Over 200 companies use Gelda's microbiological and chemical testing services
for their quality control needs. In addition, Gelda Scientific manufactures
and distributes food, health and dietary supplement products.

The Warnex Rapid Pathogen Detection System uses cutting-edge DNA-based
technology to rapidly and accurately determine the presence of pathogens in a
food sample. The system allows for the simultaneous detection of multiple
pathogens and processing of samples within 12 to 48 hours, a significant
improvement over traditional microbiology tests that currently require 5 to
7 days.

About Warnex

Warnex (www.warnex.ca) is a publicly traded (TSX: WNX) Canadian
biotechnology company devoted to protecting public health by providing
advanced diagnostic and quality control products and services to the
pharmaceutical, agri-food, and healthcare sectors. Warnex's genomics-based
technology offers a versatile detection platform that produces accurate
results rapidly, using Real-Time PCR technology combined with unique genetic
markers and software. Applications range from pathogen detection in foods to
GMO testing. Our development pipeline includes applications in the detection
of viruses, toxins, GMOs, yeasts, and molds, as well as meat speciation and
bioterrorism. Warnex's profitable and growing analytical, bioanalytical, and
clinical service groups offer a variety of quality control services, method
development and validation, contract R&D, bioavailability and bioequivalence
studies for clinical trials, and medical laboratory testing.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained in this news release are forward-looking and
are subject to numerous risks and uncertainties, known and unknown. For
information identifying known risks and uncertainties, such as market
conditions, currency, technological, financial, competitive and other
important factors that could cause actual results to differ materially from
those anticipated in the forward-looking statements, please refer to Warnex's
Annual Report under the heading Risks and Uncertainties in the Management's
Discussion and Analysis section. Consequently, actual results may differ
materially from the anticipated results expressed in these forward-looking
statements. Warnex disclaims any intention or obligation to update any
forward-looking statements, whether as a result of new information or
otherwise.

Contact Information

  • Mark J. Busgang, President & CEO, Warnex Inc., Tel: (450) 663-6724
    x.310, mbusgang@warnex.ca; Mike Polonsky, Investor Relations, The Equicom
    Group Inc., Tel: (416) 815-0700 x.231, mpolonsky@equicomgroup.com; For more
    information about Gelda Scientific, please contact: Arvind Gelda, Vice
    President, Gelda Scientific, Tel.: (905) 673-9320, arvind@gelda.com;
    Damien Boyd, Technical Sales Manager, Gelda Scientific, Tel.: (905) 673-9320,
    damien@gelda.com